 Canagliflozin
"Canagliflozin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
| Descriptor ID |
D000068896
|
| MeSH Number(s) |
D02.886.778.075 D03.383.903.075 D09.408.348.113
|
| Concept/Terms |
Canagliflozin- Canagliflozin
- Canagliflozin Hemihydrate
- Hemihydrate, Canagliflozin
Canagliflozin, Anhydrous- Canagliflozin, Anhydrous
- Anhydrous Canagliflozin
- 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973
|
Below are MeSH descriptors whose meaning is more general than "Canagliflozin".
Below are MeSH descriptors whose meaning is more specific than "Canagliflozin".
This graph shows the total number of publications written about "Canagliflozin" by people in this website by year, and whether "Canagliflozin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 2 | 2 | | 2018 | 0 | 1 | 1 | | 2019 | 1 | 1 | 2 | | 2020 | 1 | 0 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Canagliflozin" by people in Profiles.
-
Sen T, Ju W, Nair V, Ladd P, Menon R, Otto EA, Pyle L, Vigers T, Nelson RG, Arnott C, Neal B, Hansen MK, Kretzler M, Bjornstad P, Heerspink HJL. Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes. Kidney Int. 2023 10; 104(4):828-839.
-
van Raalte DH, Bjornstad P, Heerspink HJL, Persson F, Cherney DZI. Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies. Kidney Int. 2021 03; 99(3):768-770.
-
Phadke G, Kaushal A, Tolan DR, Hahn K, Jensen T, Bjornstad P, Roncal-Jimenez C, Hernando AA, Lanaspa MA, Alexander MP, Kukla A, Johnson RJ. Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report. Am J Kidney Dis. 2020 07; 76(1):144-147.
-
Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Hiatt WR, Nehler M, Fabbrini E, Kavalam M, Lee M, Neal B. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia. 2019 06; 62(6):926-938.
-
Garg SK, Giordano D. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2019 02; 21(S1):S160-S171.
-
Bonaca MP, Beckman JA. Sodium Glucose Cotransporter 2 Inhibitors and Amputation Risk: Achilles' Heel or Opportunity for Discovery? Circulation. 2018 04 03; 137(14):1460-1462.
-
Lim S, Eckel RH, Koh KK. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis. 2018 05; 272:33-40.
-
Fixen CW, Fixen DR. Managing and maintaining bone mineral density in diabetes patients with pharmacotherapy. Expert Opin Pharmacother. 2017 Dec; 18(18):2001-2006.
-
Yu T, Sungelo MJ, Goldberg IJ, Wang H, Eckel RH. Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins. Horm Metab Res. 2017 May; 49(5):400-406.
-
Trujillo JM, Nuffer WA. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Pharmacotherapy. 2017 Apr; 37(4):481-491.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|